Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Trial Profile

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2019

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Dyslipidaemias
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 26 Oct 2018 Planned End Date changed from 4 Nov 2022 to 4 Dec 2022.
    • 26 Oct 2018 Planned primary completion date changed from 4 Nov 2022 to 4 Dec 2022.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top